Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research.
References:
[1]. Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12. [2]. Reozalimab. IMGT/mAb-DB.
















